NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer
cell based therapeutics company, today announced that the company’s
Chairman & CEO, Dr. Patrick Soon-Shiong, will be giving a
keynote address at the Innate Killer Summit in San Diego on
Wednesday, March 20, 2019.
Dr. Soon-Shiong’s keynote address will provide a vision of next
generation NK cell therapies and feature a review of translational
R&D activities, state-of-the-art manufacturing requirements,
along with clinical progress.
“Over a few short years, the cell therapy industry has made
significant progress with remarkable patient responses to therapy
being seen in a few select cancer indications. While encouraging, a
significant need still exists for the majority of cancer types
where existing cell therapies have not been shown to be effective,”
said Dr. Soon-Shiong. “Natural killer cells have potent cancer cell
killing capabilities, yet are often overlooked as the immune
system’s first line of defense against cancer and other foreign
invaders. Without question, cancer patients deserve better
treatment options and I welcome the opportunity to present my
vision for next generation NK cell therapies at the Summit.”
Conference Details:
Date: Wednesday, March 20, 2019Presentation Title:
Charting a Path to Next Generation Natural Killer Cell
ImmunotherapiesPresenter: Patrick Soon-Shiong, MD, Chairman
& CEOTime: 8:30 a.m. PT
Dr. Soon-Shiong presentation will be posted on the NantKwest
website and will be available for 30 days following the Keynote.
For more information regarding NantKwest, please visit
www.nantkwest.com.
For more event information, please visit:
https://innate-killer.com/
About NantKwest
NantKwest, a member of the NantWorks ecosystem of companies, is
an innovative clinical-stage immunotherapy company focused on
harnessing the power of the innate immune system by using the
natural killer cell to treat cancer and virally induced infectious
diseases.
NantKwest is uniquely positioned to implement precision cancer
medicine, with the potential to change the current paradigm of
cancer care. Natural Killer (NK) cells are a safeguard in the human
body designed to recognize and detect cells under stress due to
cancer or viral infection. NantKwest’s “off-the-shelf” activated NK
cell platform is designed to destroy cancer and virally infected
cells from the body. The safety of our NK cells as well as their
activity against a broad range of cancers has been tested in phase
I clinical trials in Canada and Europe as well as in multiple phase
I and II clinical trials in the United States. In addition to being
a universal cell-based therapy that does not require individualized
patient sourcing or matching, our NK cell products have been
largely administered in the outpatient setting as an
“off-the-shelf” living drug.
With the capacity to grow active killer cells as a living cancer
therapy, our NK cells have been designed to induce cell death
against cancers and virally infected cells by several mechanisms,
including: innate killing, whereby all of our NK platforms
recognize the stress proteins typically found on cancer cells,
which, upon binding, release toxic granules to immediately kill
their targets; antibody-mediated killing with our haNK® platform,
which are NK cells engineered to express antibody receptors that
can bind to therapeutic antibody products, thereby enhancing the
cancer cell killing effect of that antibody; and Chimeric Antigen
Receptor directed killing using the taNK® platform, which includes
NK cells engineered to incorporate chimeric antigen receptors
(CARs) to target tumor-specific antigens found on the surface of
cancer cells. All three modes of killing (innate,
antibody-mediated, and CAR directed killing) are employed by our
t-haNK™ platform, which is an innovative combination of our aNK,
haNK® and taNK® platforms in a single product.
Our haNK®, and t-haNK™ platforms have been designed to address
certain limitations of CAR T-cell therapy including the capability
to infuse cell therapy in an outpatient setting which allows for
potential reduction of risk for serious cytokine storms and
protracted serious adverse events. In Phase I and II clinical
trials in patients with late stage cancer, our NK cells have been
administered as an investigational outpatient infusion safely with
greater than 300 infusions to date at a dose of 2 billion cells per
infusion.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs, we
believe NantKwest is uniquely positioned to be the premier
immunotherapy company and transform medicine by delivering living
drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care.
NK-92, aNK, haNK, taNK, and t-haNK are trademarks of NantKwest,
Inc.
About NantCell
NantCell is a privately held immunotherapy company with one of
the broadest portfolio of biological molecules spanning
albumin-linked chemotherapeutic, peptides, fusion proteins,
cytokines, monoclonal antibodies, adenovirus and yeast vaccine
therapies.
This platform of technologies has enabled NantCell to achieve
one of the most comprehensive late stage clinical pipelines of an
integrated platform of immunotherapy technologies addressing both
the innate (activated macrophage and natural killer cell) and the
adaptive immune system (dendritic, CD4 and CD8 killer T cells).
The pipeline constitutes over 40 immunological assets with 13
first in human immunotherapy molecules in active clinical
trials.
Currently the company is planning the enrollment in 2019 of
patients in late stage trials with 3 molecules across 17
indications in solid and liquid tumors.
In the field of oncology, NantCell’s goal is to employ a broad
portfolio of biological molecules that will enable it to activate
the endogenous NK, CD8+ T cell and develop a T cell memory cancer
vaccine to combat multiple tumor types without the use of high-dose
chemotherapy.
In the field of infectious disease, NantCell’s goal is to
develop vaccine therapy to treat and prevent diseases including
HIV, Influenza, Zika, and Ebola.
Celgene was the initial strategic investor in NantCell in 2016.
A second round crossover funding in December 2018 brought Celgene’s
investment to $105M in NantCell. In March 2019 NantCell further
expanded the crossover funding round with a $30M investment from a
sovereign wealth fund.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying the Company will be successful in improving the treatment
of cancer. Risks and uncertainties related to this endeavor
include, but are not limited to, obtaining FDA approval of our NK
cells as well as other therapeutics as part of the NANT Cancer
Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding our business are described in
detail in our Securities and Exchange Commission filings, including
in our Annual Report on Form 10-K for the year ended December 31,
2018. These forward-looking statements speak only as of the date
hereof, and we disclaim any obligation to update these statements
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190318005270/en/
Jen Hodson562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2024 to May 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From May 2023 to May 2024